Clinical trial NCT04220749: Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
Official title: A Phase II Randomized Trial for HPV-Negative Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Head and Neck Cancer
Oropharyngeal Squamous Cell Carcinoma
Keywords: Radiotherapy
Trans-Oral Surgery
HPV-Negative
Randomized
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2020-01-07
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 Arm study randomized in a 1:1 ratio
Primary purpose: TREATMENT

Brief summary: The goal of this randomized phase II study is a formal comparison of radiotherapy versus trans-oral surgery as the primary treatment of HPV-negative patients with early-stage oropharyngeal carcinoma.

Detailed description: This study is designed as a randomized phase II study. Patients will be randomized between current standard of care treatment (Arm 1) vs. TOS (Arm 2) in a 1:1 ratio. Additionally, patients will be stratified according to T stage (T1 vs. T2); N stage (N0/1 vs. N2/3)

The randomized phase II design is required for three reasons:

1. The randomization will provide an appropriate control group to serve as a comparator for the experimental arm. Historical or contemporaneous non-randomized controls would not be appropriate due to the multitude of biases that could be introduced by patient selection and other confounders.
2. A small sample size will allow for adequate power to assess for progression-free survival, and also an assessment of quality of life, overall survival and toxicity.
3. The results will allow for a decision as to whether a multi-institutional phase III trial is warranted, and inform the design of such a trial.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Willing to provide informed consent
* ECOG performance status 0-2
* Histologically confirmed squamous cell carcinoma
* HPV-negative tumor, as determined by: negative p16 status, real time PCR or in-situ hybridization. Central confirmation is not required prior to randomization. Equivocal/uncertain HPV status will be allowed on trial.
* Primary tumor site in the oropharynx (includes tonsil, soft palate, base of tongue, walls of oropharynx)
* Tumor stage: T1 or T2, with likely negative resection margins at surgery
* Nodal stage: N0-3. Patients with positive nodal disease and extranodal extension on imaging may be included at the surgeon's discretion, if the nodal disease is deemed resectable by the operating surgeon.
* Eligible for curative intent treatment, with likely negative resection margins at surgery. For patients where adequate transoral access is in question, they will first undergo an examination under anesthesia prior to randomization to ensure adequate exposure can be obtained.
* Blood work obtained within 4 weeks prior to randomization, with adequate bone marrow function, hepatic, and renal function, as determined by the investigator.
* Patient assessed by a radiation oncologist and surgeon and presented at multidisciplinary tumor board prior to randomization. If not feasible, case can be discussed with study Principal Investigator.

Exclusion Criteria:

* Serious medical comorbidities or other contraindications to radiotherapy, chemotherapy or surgery
* Prior history of head and neck cancer within 5 years
* Prior head and neck radiation at any time
* Metastatic disease
* Inability to attend full course of radiotherapy or follow-up visits
* Prior invasive malignant disease unless disease-free for at least 5 years or more, with the exception of non-melanoma skin cancer
* Unable or unwilling to complete QOL questionnaires
* Pregnant or lactating women

Primary outcomes:
measure: Disease-Specific Survival
timeFrame: 5 years
Secondary outcomes:
measure: Overall Survival
timeFrame: 5 years
measure: Progression-Free Survival
timeFrame: 5 years
measure: Local-Regional Failure
timeFrame: 5 years
measure: Distant Failure
timeFrame: 5 years
measure: Any Failure
timeFrame: 5 years
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Quality of Life
timeFrame: Baseline to 5 years follow up
measure: Toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4
timeFrame: Randomization until 5 years follow up
measure: Feeding tube rate at 1 year
timeFrame: Baseline to 1 year post treatment
measure: CTCAE Dysphagia Grade
timeFrame: Baseline to 5 years post treatment
Other outcomes:
Locations:
city: London
country: Canada
facility: London Regional Cancer Program
state: Ontario
Study officials:
affiliation: London Regional Cancer Program, London Health Sciences Centre
name: Danielle MacNeil, M.D.
role: PRINCIPAL_INVESTIGATOR
References: